Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | VHL | P40337 | 3/20 | 0.42 |
| ▸ | ELOC | Q15369 | 2/20 | 0.42 |
| ▸ | ELOB | Q15370 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | PEPD | P12955 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292790 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL806128 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL3371956 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL13318866 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL20120875 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL8015855 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL8253158 | 1.00 | ELANE (0.44) | ELANEALDH1A1VHLELOCELOB | |
| SCHEMBL10347003 | 0.90 | PEPD (0.47) | ELANEVHLELOCELOBMMP2 | |
| SCHEMBL13744721 | 0.90 | PEPD (0.47) | ELANEVHLELOCELOBMMP2 | |
| SCHEMBL13817413 | 0.89 | ANPEP (0.56) | ELANEVHLELOCELOBMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | CRBN, VHL, UBQLN2 | ELANE 3960/4885ALDH1A1 4249/4885VHL 2/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | ELANE 3960/4885ALDH1A1 4249/4885VHL 2/4885 |
| US-12171831-B2 | Compounds and methods for the targeted degradation of bromodomain- containing proteins | BRPF3, STUB1, BRDT | ELANE 1405/4885ALDH1A1 3365/4885VHL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.